Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Bringing Medicines to Market Faster Through Analytics & Machine Learning

Traditional medicine isn’t generally taken very seriously in the United States. However, Dr. Andrea Small-Howard, President and CSO at GB Sciences explained that “65% of the world still use traditional medicine either as their sole medicine or in conjunction with Western medicine.” Depending on the source, traditional plant-based medicine dates back as far as…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Traditional medicine isn’t generally taken very seriously in the United States. However, Dr. Andrea Small-Howard, President and CSO at GB Sciences explained that “65% of the world still use traditional medicine either as their sole medicine or in conjunction with Western medicine.” Depending on the source, traditional plant-based medicine dates back as far as 60,000 years whereas Western medicine is a mere 3,000 years old.

Kevin Stevenson, I Don’t Care podcast host, sat down with the distinguished Dr. Small-Howard to discuss her work in the plant-based medicine industry. Dr. Small-Howard will also discuss the digital transformation curve with GB Sciences AI-based drug discovery platform PhAROS. This podcast is of great interest due in part to Dr. Small-Howard’s extensive resume. In fact, it is so extensive that the following introduction from her LinkedIn profile barely highlights her expertise.

“Dr. Andrea Small-Howard has 25 years of scientific research and executive experience in the biopharma industry supervising research & development, manufacturing, and quality control divisions in the US and China. Dr. Small-Howard has taken novel biological products from ideation through commercialization. She has been named an inventor on seventy+ patent applications, taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (‘US FDA’), and orchestrated commercial licensing deals.”

Listeners might think that they would not be able to understand or relate to such a well-educated scientific mind, but nothing could be further from the truth. Dr. Small-Howard is an engaging speaker filled with enthusiasm for her chosen line of work and her mission to normalize plant-based medicine in the United States.

“My background is in biochemistry, so I sort of see the world through a different lens and I’ve always been obsessed with the power of plant-based medicines. Traditional medicine is often overlooked as being a really powerful force here in the United States,” said Dr. Small-Howard. The doctor joined GB Sciences in 2014 to take plant-based medicine to the next level by utilizing science to maximize the potential of the cannabis plant.

More Like This Story:

Behavioral Health Is Stepping Out of the Shadows of Healthcare

Tearing Down the Barrier of Prior Authorization Through Automation

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel →

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

IQVIA's new white paper maps how digital health technologies can reshape CNS clinical trial endpoints

IQVIA's new white paper maps how digital health technologies can reshape CNS clinical trial endpoints

IQVIA's white paper provides a framework for validating digital endpoints in CNS clinical trials, focusing on digital health technologies such as sensors, software, and connected devices. These technologies have the potential to reshape clinical trial endpoints in neurological studies. The white paper aims to guide the integration of digital health solutions in measuring clinical outcomes.

  • 01Digital health technologies like sensors and software can reshape CNS clinical trial endpoints.
  • 02Validating digital endpoints in clinical trials is crucial for integrating technology in CNS studies.
  • 03IQVIA offers a framework for using connected devices in clinical research.

Jul 16, 2026

Clinical AI safety, intelligent ventilators, and payment accuracy: health tech's big moves on July 15

Clinical AI safety, intelligent ventilators, and payment accuracy: health tech's big moves on July 15

On July 15, significant health technology announcements highlighted advancements in AI safety benchmarks, smarter critical-care equipment, and autonomous front-office tools. These developments indicate a strong push towards integrating intelligent systems in healthcare to enhance patient care and operational efficiency.

  • 01AI safety benchmarks are being established to ensure intelligent technologies are safely integrated into healthcare systems.
  • 02Intelligent ventilators and smarter critical-care tools are being developed to improve patient outcomes in healthcare settings.
  • 03Autonomous front-office tools are being introduced to streamline administrative tasks in healthcare facilities.

Jul 16, 2026

Saudi Arabia's digital health push: what a $77 billion market means for enterprise operators

Saudi Arabia's digital health push: what a $77 billion market means for enterprise operators

Saudi Arabia is set to expand its healthcare market with expenditures predicted to reach $77.1 billion by 2027, partly driven by advancements in digital health technologies. Digital health revenue is expected to exceed $1 billion by 2029, with an anticipated user base of 16.2 million. This growth represents significant opportunities for enterprise operators in the healthcare sector.

  • 01Saudi Arabia's healthcare spend is projected to reach $77.1 billion by 2027.
  • 02The digital health market in Saudi Arabia is expected to generate over $1 billion in revenue by 2029.
  • 03An estimated 16.2 million users will engage with digital health services in Saudi Arabia by 2029.

Jul 16, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512